The present study evaluated whether type 2 diabetes (T2D) attenuates muscarinic and/or nicotinic cutaneous vasodilatation and sweating as well as purinergic cutaneous vasodilatation.
INTRODUCTION
Type 2 diabetes (T2D) is a metabolic disorder characterized by insulin resistance and hyperglycaemia. Furthermore, T2D is a well-established risk factor for cardiovascular disease (Gu, Cowie, & Harris, 1999) Acetylcholine-induced forearm vasodilatation (Mäkimattila et al., 1999; Woodman, Watts, Playford, Best, & Chan, 2005) . In addition, T2D is associated with altered cutaneous vascular (microvascular) responses (Caballero et al., 1999; Colberg, Stansberry, McNitt, & Vinik, 2002; Sokolnicki, Roberts, Wilkins, Basu, & Charkoudian, 2007) , although this is not always observed, especially when evaluated in Experimental Physiology. 2018;103:212-221.
wileyonlinelibrary.com/journal/ephrelatively healthy individuals with well-controlled T2D and free of co-morbidities such as peripheral neuropathy (Fujii et al., 2017c; Sokolnicki et al., 2007) . To date, there remains a paucity of information on how, if at all, T2D might modulate the mechanisms regulating cutaneous blood flow.
Studies have shown that T2D attenuates acetylcholine-induced cutaneous vasodilatation (Caballero et al., 1999; Pek et al., 2017; Veves et al., 1998) , a well-established index of microvascular endothelial function, although this is not a universal finding (Brooks et al., 2008a; Brooks, McLennan, Twigg, & Yue, 2008b) . Given that acetylcholine activates both muscarinic and nicotinic receptors (Pappano, 2011) , whether the impaired vasodilatory response to acetylcholine (Caballero et al., 1999; Pek et al., 2017; Veves et al., 1998 ) is attributable to either altered muscarinic or nicotinic receptor function, or a combination of both, cannot be discerned. Nicotine can activate nicotinic receptors. Methacholine is frequently used as an acetylcholine mimetic, but selectively activates muscarinic receptors, with little influence on nicotinic receptors. Hence, assessing cutaneous vasodilatation in response to nicotine (Fujii et al., 2017b) and methacholine separately would elucidate whether T2D affects muscarinic and nicotinic cutaneous vasodilatation, respectively.
Type 2 diabetes reduces ATP production (Petersen, Dufour, & Shulman, 2005; Stump, Short, Bigelow, Schimke, & Nair, 2003) , potentially reducing ATP-sensitive purinergic receptor activation. It is therefore plausible that T2D leads to altered purinergic receptor function, which is known to contribute to cutaneous vascular regulation (Fujii et al., 2015b; Fujii, Halili, Singh, Meade, & Kenny, 2015a; Kalsi et al., 2017; Wingo, Brothers, Del Coso, & Crandall, 2010) . However, no study to date has evaluated whether T2D
modulates the cutaneous vascular response to purinergic receptor activation elicited by ATP. In human skin, low concentrations of ATP may cause vasoconstriction (Lang, Krajek, & Smaller, 2017) , whereas high concentrations have been shown to induce a dose-dependent vasodilatation (Fujii et al., 2015a (Fujii et al., , 2015b Kalsi et al., 2017; Wingo et al., 2010) without affecting sweat rate (Fujii et al., 2015a (Fujii et al., , 2015b .
Furthermore, previous work has demonstrated that ATP-induced vasodilatation in forearm conduit arteries is impaired in individuals with T2D (Thaning et al., 2010) . It is possible, therefore, that T2D might attenuate ATP-mediated cutaneous vasodilatation.
Human skin possesses eccrine sweat glands that are important for heat dissipation and therefore the regulation of core body temperature. Most, but not all, previous studies have shown that T2D impairs the local sweating response during whole-body heat stress or acetylcholine administration (Caselli, Rich, Hanane, Uccioli, & Veves, 2003; Fealey, Low, & Thomas, 1989; Levy, Reid, Abraham, & Rowley, 1991; Petrofsky, Lee, Patterson, Cole, & Stewart, 2005) .
Blunted acetylcholine-induced sweating in individuals with T2D
suggests attenuated peripheral sweat gland function. However, given that acetylcholine activates both muscarinic and nicotinic receptors, as mentioned above, it remains to be determined whether T2D impairs muscarinic and/or nicotinic sweating. In the present study,
we examined muscarinic and nicotinic cutaneous vasodilatation and sweating and purinergic cutaneous vasodilatation in older adults with
New Findings
• What is the central question of this study?
It remains to be determined whether type 2 diabetes attenuates muscarinic and nicotinic cutaneous vasodilatation and sweating as well as purinergic cutaneous vasodilatation.
• What is the main finding and its importance?
We show that type 2 diabetes specifically attenuates purinergic cutaneous vasodilatation without influencing muscarinic and nicotinic cutaneous vasodilatation and sweating. Our results provide valuable new information regarding the receptor-specific influence of type 2 diabetes on microvascular and sudomotor function.
T2D. We hypothesized that T2D attenuates cutaneous vasodilatation and sweating in response to muscarinic and nicotinic agonists as well as ATP-induced cutaneous vasodilatation. 
METHODS

Ethical approval
Participants
Thirteen older adults diagnosed with T2D for >5 years and 12 healthy non-diabetic older adults (Control) were tested in this study.
Participants were medically screened and were required to complete questionnaires to assess their eligibility to participate in the study.
Only individuals who were not engaged in regular physically activity were tested. All participants performing >2 days of continuous activity of at least 20 min per session were excluded from the study. None of the participants reported a history of specific medical conditions (cystic fibrosis transmembrane conductance regulator mutations, skin disorders, uncontrolled hypertension, heart disease and/or peripheral neuropathy), were smoking or had smoked in the past 10 years. Participants with T2D were taking the following medications 
Experimental session
Before the experimental session, all participants refrained from consuming over-the-counter medications for >48 h (e.g. non-steroidal anti-inflammatory drugs, vitamins and minerals), alcohol and caffeine for >24 h, and performing any strenuous physical activity for >12 h. Furthermore, they were restricted from consuming food for Approximately 10 min after the placement of the three microdialysis fibres, all skin sites were perfused with lactated Ringer solution (Baxter, Deerfield, IL, USA) for a period of >80 min to allow for the trauma associated with fibre/needle insertion to subside. Perfusion at each of the skin sites was maintained at a rate of 4.0 l min −1 using a micro-infusion pump (model 4004; CMA Microdialysis, Solna, Sweden).
Thereafter, a 10 min baseline measurement was initiated, after which pharmacological agents were administered at the three intradermal forearm skin sites as follows: (i) of the agents were determined based on our previous work for methacholine (Fujii et al., 2015a , nicotine (Fujii et al., 2017a) and ATP (Fujii et al., 2015b) 
Measurements
Sweat capsules were attached with the aid of topical skin glue (Collodion HV; Mavidon Medical, Lake Worth, FL, USA) on the intradermal microdialysis skin site, each covering 1.1 cm 2 area of the skin.
This capsule was specifically designed for use with intradermal microdialysis (Meade et al., 2016 ) 
Data analysis
Baseline CVC and sweat rate were obtained by averaging values over the final 5 min of the 10 min baseline measurement at each of the three skin sites before commencing any receptor agonist administration. The 
Statistical analysis
Statistical analyses were conducted using SPSS 24 (IBM, Armonk, NY, USA 
RESULTS
Participant characteristics
Age, height, body mass and resting mean arterial pressure were all matched between groups (all P > 0.05; Table 1 ).
Cutaneous vascular conductance
No between-group differences in baseline CVC were observed (all P > 0.05; Figure 1a ). Relative to baseline, CVC increased in response to the administration of each agonist at all concentrations in both groups Figure 2c ). Likewise, maximal absolute CVC was lower in T2D individuals (P = 0.04; Figure 3 ).
TA B L E 1 Participant characteristics
Characteristic
Control T2D
Number of subjects (male/female) 12 (3/9) 13 (3/10) Age (years) 60 ± 8 62 ± 10 Height (m) 1.68 ± 0.10 1.64 ± 0.06
Body mass (kg) 80 ± 13 84 ± 13
Mean arterial pressure (mmHg) 95 ± 8 8 9 ± 7
HbA 1C (%) -7.5 ± 0.9
Duration of diabetes (years) n.a. 12.8 ± 9.9
Abbreviations: HbA 1C , glycosylated haemoglobin; n.a., not applicable; and T2D, type 2 diabetes. All values are expressed as means ± SD. Age, height, body mass, and mean arterial pressure did not differ between groups (all P > 0.05).
Sweating
Baseline sweat rate was higher in the T2D relative to the Control group (P = 0.03; Figure 1b ). Sweat rate was elevated above baseline when methacholine and nicotine were administered at all doses in both groups (all P ≤ 0.05; Figure 4a ,b), except that no significant increase in sweat rate was observed with 11 and 33 mM nicotine in the Control group and with 33 mM nicotine in the T2D group (P = 0.08-0.14; Figure 4b ). Administration of ATP did not influence sweat rate in either group (all P > 0.05; Figure 4c ). There were no between-group differences in sweat rate at any treatment site (Figure 4 ).
DISCUSSION
We showed that older adults with well-controlled T2D demonstrated similar methacholine-and nicotine-mediated cutaneous vasodilatation and sweating responses relative to their healthy age-matched counterparts. However, ATP-induced cutaneous vasodilatation was attenuated in T2D individuals. Furthermore, we showed that cutaneous vasodilatation elicited by sodium nitroprusside, a nitric oxide donor, was attenuated in older individuals with T2D. Taken together, we showed that T2D is associated with the attenuation of purinergic cutaneous vasodilatation, with no effect on muscarinic and nicotinic cutaneous vascular and sweating responses.
Cutaneous vasodilatation
Both healthy older adults and those with T2D displayed dosedependent augmentations in cutaneous vasodilatation in response to exogenous ATP (Figure 2c ), findings consistent with observations in young adults (Fujii et al., 2015b) . These responses appear to be mediated via the activation of purinergic receptors (i.e. P2Y) located on the endothelial cells, as was demonstrated in resistance artery of human skin in vitro (Martin, Thom, & Sever, 1991) .
However, the magnitude of ATP-induced cutaneous vasodilatation was attenuated in the individuals with T2D relative to their healthy agematched counterparts (Figure 2c ), suggesting that T2D attenuates purinergic cutaneous vasodilatation. Our findings build upon a previous report showing that T2D reduces ATP-induced vasodilatation in human conduit arteries (Thaning et al., 2010) . Altogether, these findings indicate that T2D may impair both micro-and macrovascular responses to ATP in humans in vivo.
We previously reported that nitric oxide contributes to ATPinduced cutaneous vasodilatation (Fujii et al., 2015b) . Thus, one may surmise that the attenuated purinergic cutaneous vasodilatation measured in individuals with T2D could be a result of reduced nitric oxide-dependent vasodilatation. This is a reasonable assumption, given our observations of reduced vascular smooth muscle responsiveness to sodium nitroprusside, a nitric oxide donor, in the T2D group (Edwards, Feletou, & Weston, 2010) . Given that cyclo-oxygenase does not appear to be involved in the ATP-induced cutaneous vasodilatation (Fujii et al., 2015b) , cutaneous vasodilatation associated with endothelium-dependent hyperpolarization may be largely impaired in this population. Further research is required to evaluate this possibility.
We found that cutaneous vasodilatation elicited by methacholine infusion was similar between groups ( Figure 2a ). This is consistent with previous work using acetylcholine (Brooks et al., 2008a (Brooks et al., , 2008b , although other studies reported that acetylcholine-mediated cutaneous vasodilatation is impaired by T2D (Arora et al., 1998; Caballero et al., 1999; Veves et al., 1998) . Although the underlying reasons for the disparate findings are unclear, it is important to note that, to the best of our knowledge, we are the first to evaluate methacholine-induced cutaneous vasodilatation in individuals with T2D, whereas all other studies used acetylcholine (Caballero et al., 1999; Fuchs, Dupon, Schaap, & Draijer, 2017; Pek et al., 2017; Veves et al., 1998) . Methacholine specifically activates muscarinic receptors with little influence on nicotinic receptors, whereas acetylcholine has been shown to stimulate both muscarinic and nicotinic receptors (Pappano, 2011) . Hence, our study was able to separate distinct activation of muscarinic and nicotinic receptors in mediating cutaneous vasodilatation, and suggests that muscarinic cutaneous vasodilatation is not influenced by T2D.
Muscarinic (i.e. methacholine)-induced cutaneous vasodilatation is
partly (20-40%) mediated by nitric oxide, with no contribution of cyclo-oxygenase . Given that vascular smooth muscle responsiveness to nitric oxide is reduced by T2D, as discussed above, muscarinic receptor-mediated cutaneous vasodilatation could be also attenuated in individuals with T2D, although this was not the case in the present study (Figure 2a ). It might be that T2D upregulates nitric oxide-independent vasodilatation (e.g. vasodilatation associated with cyclo-oxygenase and/or endothelium-dependent hyperpolarization), compensating for the reduced nitric oxide-dependent vasodilatation.
Nicotine-induced cutaneous vasodilatation did not differ between groups (Figure 2b ), suggesting that T2D has no effect on nicotinic cutaneous vasodilatation. In contrast to purinergic and muscarinic cutaneous vasodilatation, nitric oxide is not involved in the regulation of nicotinic cutaneous vasodilatation (Fujii et al., 2017a) . However, nicotinic receptor activation can facilitate acetylcholine release via a cholinergic axon reflex (Schlereth, Brosda, & Birklein, 2005) . In keeping with this prior observation, we recently reported that muscarinic receptor blockade abolished nicotinic cutaneous vasodilatation at 1.2-11 mM nicotine (Fujii et al., 2017a) . Thus, the lack of cutaneous vasodilatory response with the administration of nicotine at concentrations of 1.2-11 mM in individuals with T2D in the present study might suggest that T2D does not modulate the cholinergic axon reflex. It should be noted that cutaneous vasodilatation elicited by high doses of nicotine (33-100 mM) occurs independently of muscarinic receptors (Fujii et al., 2017a) . Nicotinic receptor activation on cutaneous vascular endothelial cells (Hagforsen, Edvinsson, Nordlind, & Michaëlsson, 2002 ) might underpin this vasodilatory response and, based on our results, T2D might not alter endothelial nicotinic receptor function.
The attenuated vascular smooth muscle responsiveness to nitric oxide in the T2D individuals (Figure 3 ) is in line with previous studies (Caballero et al., 1999; Sokolnicki et al., 2007; Williams, Cusco, Roddy, Johnstone, & Creager, 1996) . We do not know the under- ). Furthermore, a previous study reported that T2D does not alter skin capillary density (Jaap, Shore, Stockman, & Tooke, 1996) .
Thus, our observation of a lower cutaneous perfusion during sodium nitroprusside administration does not appear to be attributable to cutaneous capillary rarefaction.
Sweating
Consistent with the healthy young individuals of our previous work (Fujii et al., , 2017a , methacholine and nicotine, but not ATP, activated sweating in the present study (Figure 4 ). Regarding the between-group comparison, methacholine-induced sweating was similar between groups (Figure 4a ), and this is consistent with recent work showing that local sweating in individuals with T2D was similar to their age-matched counterparts as assessed during a passive- (Kenny, Sigal, & McGinn, 2016) and exercise-induced (Fujii et al., 2017c) heat stress. Moreover, the present study showed that nicotinic sweating did not differ between groups (Figure 4b ). We recently demonstrated that nicotinic sweating is exclusively mediated via the activation of muscarinic receptors in young healthy individuals at doses of 1.2-100 mM (Fujii et al., 2017a) ; a response possibly associated with axon-reflex-induced acetylcholine release. Thus, consistent with our observations of nicotinic cutaneous vasodilatation, we also show that T2D does not appear to alter the cholinergic axon reflex in human skin.
Baseline . We do not know why the higher sweat rate in individuals with T2D was observed in thermoneutral conditions only. The higher sweat rate in the T2D group in the present study might be associated with regional changes in sweat rate with T2D characterized by a relative hyperhidrosis on the upper body (including forearm), and lower body anhidrosis (Fealey et al., 1989) . However, we did not assess sweating responses on the lower body. Thus, future studies are necessary to delineate the physiological mechanisms underpinning the higher resting forearm sweat rate in individuals with T2D.
Consistent with our previous work (Fujii et al., 2017a) , in both groups we observed that nicotinic sweating demonstrates a transient pattern of response. This might indicate rapid desensitization of nicotinic receptors. Furthermore, nicotinic sweating is not dose dependent, such that the change in sweat rate was similar across the different doses administered (Figure 4b ). It might be that nicotinic sweating shows tachyphylaxis, thereby attenuating subsequent nicotinic sweating. Further work is required to assess these potential mechanisms.
Considerations
We evaluated cutaneous vascular and sweating responses in relatively healthy individuals with well-controlled T2D and no peripheral neuropathy. This might explain why we did not observe an attenuation in muscarinic and nicotinic cutaneous vasodilatation and sweating in our T2D participants. It has been shown that individuals with T2D who have peripheral neuropathy exhibit greater attenuation of cutaneous vascular and sweating responses in comparison to those without peripheral neuropathy (Ishibashi et al., 2014; Pek et al., 2017) . It is therefore possible that muscarinic and nicotinic differences in cutaneous vasodilatation and sweating would be observed in older diabetic adults with poor glucose control and/or peripheral neuropathy. Regardless, in the present study we observed marked attenuations in cutaneous vasodilatation in response to ATP and sodium nitroprusside, suggesting deterioration of the cutaneous vascular function even in relatively healthy adults with T2D.
All participants with T2D were on prescription medications in the present study. We do not know whether the chronic intake of prescription medications modulates our results. However, we did not observe between-group differences in CVC and sweat rate during methacholine and nicotine administration. Moreover, previous work showed a similar pattern of whole-body (Kenny et al., 2013) and local (Fujii et al., 2017c; Kenny et al., 2013) heat loss responses in individuals with T2D regardless of differences in prescribed medication. Although this may suggest that medication use and or type might not greatly modulate local control of sweating and cutaneous perfusion in this group, future studies must be conducted to assess this response.
Although we did not assess any index of physical activity level, only those individuals who were not engaged in regular physical activity were permitted to participate in the study. Thus, we do not believe that physical activity levels differed markedly between groups. Moreover, a recent study showed that physical activity level might not be an important mediator of cutaneous vasodilation and sweating (Amano, Fujii, Louie, Meade, & Kenny, 2017) . In particular, peak oxygen uptake, an index of aerobic capacity, is not associated with the magnitude of nitric oxide-dependent sweating in older adults. Nevertheless, further study is warranted to elucidate whether levels of physical activity modulate muscarinic, nicotinic and purinergic cutaneous vasodilatation and/or sweating.
Perspective and significance
The present study demonstrates that ATP-induced cutaneous vasodilatation is attenuated by T2D albeit in the absence of changes in muscarinic and nicotinic cutaneous vasodilatation and sweating. Given Adults with T2D often display hyperglycaemia that can be attributed to reduced insulin-mediated vasodilatation and glucose removal (Gudbjörnsdóttir, Sjöstrand, Strindberg, & Lönnroth, 2005; Scheede-Bergdahl, Olsen, Reving, Boushel, & Dela, 2009 ). However, the mechanisms underpinning the impaired insulin-mediated vasodilatation remain unclear. Insulin-induced vasodilatation may be linked with purinergic mechanisms, as insulin can increase ATP production (Stump et al., 2003) . Thus, impaired purinergic vasodilatation might underlie the blunted insulin-mediated vasodilatation and glucose removal in individuals with T2D. More work is required to elucidate these possibilities.
Conclusion
We showed that T2D impairs purinergic cutaneous vasodilatation, whereas no effect on muscarinic and nicotinic cutaneous vasodilatation and sweating was observed.
